A poster session was presented that indicated an indirect comparison of TAK-788 vs. real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. The intervention TAK 788 is produced by Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. TAK 788 is a small molecule, and in the clinical trial study - nct02716116, a total of 99 patients were enrolled.
Despite a more heavily pretreated patient population, the efficacy of TAK-788 Takeda in patients with refractory non-small cell lung cancer with EGFR exon 20 insertions appears better than other second-line treatment options used in the real-world setting.
Among pretreated patients with non-small cell lung cancer with EGFR exon 20 insertions, indian mobocertinib, i.e. TAK-788, demonstrated prolonged PFS and higher ORR compared with other second-line treatment options used in a real-world setting.
Abstract No. 8509 - A poster discussion session stated updated results from a phase III study of BELLINI venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. The intervention venetoclax is manufactured by Abbvie, Inc, and the technology utilized is a small molecule. BELLINI venetoclax addition significantly improved PFS but resulted in increased mortality vs. Pbo in the total population.
The Greatest PFS improvement with Ven was observed in pts with t(11;14) or BCL2high gene expression, where Ven shows a favorable benefit-risk profile. The study continues for the final OS analysis. BELLINI study venetoclax has positioned itself as a transformative intervention for patients with t(11;14)-positive mutation however, the risk of higher mortality in a few subgroups of patients is worrying.
Abstract No. 5001 - An oral abstract session demonstrated the results of the KEYNOTE 426 study where pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) was administered. KEYNOTE 426 included axi pembro rcc (axitinib + pembrolizumab in Renal Cell Carcinoma) manufactured by Merck & Co. using the immune checkpoint technology inhibitor (ICI).
Axi pembro rcc continued to demonstrate superior and durable antitumor activity vs sunitinib in pts with first-line RCC with a 27-mo median follow up, no new safety signals were observed. The interesting thing about the study is that the rate of complete responses (CRs) has increased, and these are the best responses you can wish for. There were no new signs of toxicities. It's cemented again: pembrolizumab and axitinib are a very reasonable first choice in untreated RCC.
Also read- Smoking Cessation and Nicotine Addiction Market | Orthopedic Power Devices Market | Varicose Vein Treatment Devices Market | TRK Fusion Cancer Market | Mantle Cell Lymphoma Market | Peripheral Nerve Repair Devices Market | Surgical Mask & Respirator Market | Surgical Lasers Market | Seasonal Allergic Rhinitis Market | Plaque Modification Devices Market | Percutaneous Arterial Closure Device Market | Chronic Pulmonary Infections Market | Surgical Energy Instruments Market | Biopsy Devices Market | Dyspepsia Market
